Drug Profile
Research programme: spinal muscular atrophy therapeutics - Paratek Pharmaceuticals/Families of SMA
Alternative Names: PKT SMA 01; PTK-SMA-01Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Families of SMA; Paratek Pharmaceuticals
- Class Small molecules; Tetracyclines
- Mechanism of Action Survival of motor neuron 1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 21 Sep 2023 Paratek Pharmaceuticals has been acquired by Gurnet Point Capital and Novo Holdings
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
- 17 Jun 2008 Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals have extended their research collaboration for another year